Targeting both immune cell activation (e.g, AP-1 or JAK-STAT signaling) and ontogeny, as well as monocyte-neutrophil crosstalk, may have therapeutic utility in preventing pulmonary complications in sepsis survivors. This evidence concerns the gene FOS and Sepsis.